Pediatric subjects participating in HHS-funded or FDA-regulated studies are afforded additional protections not codified in subpart A of the Federal Policy for the Protection of Human Subjects (the Common Rule). Subpart D—which describes additional considerations when children are research subjects—introduces new terms like assent, parental permission, minor increase over minimal risk, prospect of direct benefit, and one and two parent signatures.
When assessing risk for pediatric studies, an IRB must evaluate all procedures and interventions against four categories of research. To make this determination properly, the IRB has to decide on two inconsistently defined concepts: 1) is there prospect of direct benefit? Or 2) does the research present minimal risk or a minor increase over minimal risk? During this webinar, speakers will address such questions and more. (Presented on September 18, 2019)
- Overview of pediatric subpart D regulations
- Approvable research categories
- Prospect of direct benefit
- Minimal risk and minor increase over minimal risk
- Interactive case studies for the IRB
What will I learn?
After attending this webinar, you will be able to:
- Identify the criteria for pediatric approvable research
- Compare and contrast minimal risk with minor increase over minimal risk
- Evaluate if the interventions or procedures in a protocol hold the prospect of direct benefit
Who should attend?
IRB staff and members will benefit from attending this webinar. No prerequisite knowledge is required, but those who have wrestled with issues of risk determination in pediatric studies will benefit in particular.
Webinar participants holding the Certified IRB Professional (CIP®) credential may apply 1.25 continuing education credits towards CIP recertification. Learn More »
Thank You to our Webinar Supporter!
Advarra is the premier provider of IRB, IBC and global research quality and compliance consulting services in North America. We provide customized, dedicated services for more than 3100 institutions, academic medical centers and research consortia and are fully sIRB ready. By delivering exceptional client service, innovative technology and unmatched regulatory expertise, Advarra provides integrated research compliance capabilities to help make research altogether better.
For more information, please visit advarra.com.
Mention of commercial products, processes, or services on our website or in our email publications should not be construed as an endorsement or recommendation.
Access to purchased content will be available for 30 days after the date of purchase. After 30 days, access to the content will be removed, but users will retain access to any certificates of attendance earned. Content purchased prior to January 1, 2021 will remain available indefinitely. After access has expired, users can purchase an additional 30 days of access.
Please note that this content is also part of a bundle. Click here to see the full bundle array.
If you'd prefer a paper form, please click here. Please send the completed form to email@example.com.